safest glp 1 drugs New GLP-1 Guidelines for Type 2 Diabetes in 2025 Researchers find GLP-1 medications safe

Resmetirom received FDA approval for the fibrotic stage, but the steatosis stage, where the vast majority of patients sit, has no approved pharmacological intervention

If GLP-1 medications have become too expensive, too frustrating, or simply not effective enough, it may be time to compare your surgical options

Semaglutide 2.4 mg weekly, assessed in 17,604 individuals with body mass index (BMI) 27 kg/m and cardiovascular disease (CVD), resulted in 8.51% weight loss at 104 weeks and a 20% reduction in nonfatal Myocardial Infarction (MI), stroke, and cardiovascular death

Patients should plan for the program to end on December 31, 2027 unless extended

This effect has been observed both in vitro and in vivo